Aadi Bioscience Inc
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa… Read more
Aadi Bioscience Inc (AADI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.287x
Based on the latest financial reports, Aadi Bioscience Inc (AADI) has a cash flow conversion efficiency ratio of -0.287x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.05 Million) by net assets ($52.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aadi Bioscience Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Aadi Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aadi Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aadi Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KMH Hitech Co. Ltd
KQ:052900
|
0.058x |
|
Mustang Industrial
TWO:5460
|
0.025x |
|
Chang Ho Fibre Corp
TW:1468
|
0.022x |
|
Zhong An Group Limited
F:35Z
|
0.005x |
|
Duro Felguera
MC:MDF
|
0.041x |
|
ODTech Co. Ltd
KQ:080520
|
-0.012x |
|
First Ship Lease Trust
PINK:FSLUF
|
0.083x |
|
Favelle Favco Bhd
KLSE:7229
|
0.041x |
Annual Cash Flow Conversion Efficiency for Aadi Bioscience Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of Aadi Bioscience Inc from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-59.55 Million | -1.135x | -100.08% |
| 2023-12-31 | $105.19 Million | $-59.66 Million | -0.567x | -80.96% |
| 2022-12-31 | $158.38 Million | $-49.64 Million | -0.313x | -90.67% |
| 2021-12-31 | $136.41 Million | $-22.42 Million | -0.164x | -116.09% |
| 2020-12-31 | $-12.43 Million | $-12.70 Million | 1.022x | +256.49% |
| 2019-12-31 | $36.54 Million | $-23.85 Million | -0.653x | -559.45% |
| 2018-12-31 | $58.67 Million | $-5.81 Million | -0.099x | +90.86% |
| 2017-12-31 | $17.44 Million | $-18.88 Million | -1.083x | -185.86% |
| 2016-12-31 | $-12.46 Million | $-15.72 Million | 1.261x | +127.74% |
| 2015-12-31 | $3.93 Million | $-17.88 Million | -4.548x | -3123.00% |
| 2014-12-31 | $-155.04K | $-23.32K | 0.150x | -23.77% |
| 2013-12-31 | $-124.24K | $-24.52K | 0.197x | -17.21% |
| 2012-12-31 | $-95.54K | $-22.77K | 0.238x | -15.56% |
| 2011-12-31 | $-68.18K | $-19.24K | 0.282x | -39.87% |
| 2010-12-31 | $-40.99K | $-19.24K | 0.469x | -59.14% |
| 2009-12-31 | $-18.60K | $-21.37K | 1.149x | -- |